Yu J, Cilfone N A, Large E M, Sarkar U, Wishnok J S, Tannenbaum S R, Hughes D J, Lauffenburger D A, Griffith L G, Stokes C L, Cirit M
Department of Biological Engineering, Massachusetts Institute of Technology Cambridge, Massachusetts, USA.
CN Bio Innovations Welwyn Garden City, UK.
CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):585-94. doi: 10.1002/psp4.12010. Epub 2015 Oct 5.
Our goal in developing Microphysiological Systems (MPS) technology is to provide an improved approach for more predictive preclinical drug discovery via a highly integrated experimental/computational paradigm. Success will require quantitative characterization of MPSs and mechanistic analysis of experimental findings sufficient to translate resulting insights from in vitro to in vivo. We describe herein a systems pharmacology approach to MPS development and utilization that incorporates more mechanistic detail than traditional pharmacokinetic/pharmacodynamic (PK/PD) models. A series of studies illustrates diverse facets of our approach. First, we demonstrate two case studies: a PK data analysis and an inflammation response--focused on a single MPS, the liver/immune MPS. Building on the single MPS modeling, a theoretical investigation of a four-MPS interactome then provides a quantitative way to consider several pharmacological concepts such as absorption, distribution, metabolism, and excretion in the design of multi-MPS interactome operation and experiments.
我们开发微生理系统(MPS)技术的目标是通过高度集成的实验/计算范式,为更具预测性的临床前药物发现提供一种改进方法。成功将需要对MPS进行定量表征,并对实验结果进行机制分析,以便将由此产生的见解从体外转化到体内。我们在此描述一种用于MPS开发和应用的系统药理学方法,该方法比传统的药代动力学/药效学(PK/PD)模型纳入了更多的机制细节。一系列研究说明了我们方法的不同方面。首先,我们展示两个案例研究:一个PK数据分析和一个炎症反应——聚焦于单个MPS,即肝脏/免疫MPS。基于单个MPS建模,对四MPS相互作用组的理论研究随后提供了一种定量方法,以在多MPS相互作用组操作和实验设计中考虑诸如吸收、分布、代谢和排泄等几个药理学概念。